Coronary heart disease secondary prevention

Revision as of 05:32, 1 October 2012 by C Michael Gibson (talk | contribs)
Jump to navigation Jump to search

Coronary heart disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Coronary heart disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening and Risk Stratification

Natural History, Complications and Prognosis

Diagnosis

Pretest Probability

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Coronary heart disease secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Coronary heart disease secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Coronary heart disease secondary prevention

CDC on Coronary heart disease secondary prevention

Coronary heart disease secondary prevention in the news

Blogs on Coronary heart disease secondary prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Coronary heart disease secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Physical Activity Recommendations

Encourage 30 to 60 minutes of moderate intensity aerobic activity such as brisk walking, on most, preferably all, days of the week. Advise medically supervised programs for high-risk patients (e.g. recent acute coronary syndrome or revascularization, heart failure)

Weight Management

  • Goal: BMI 18.5 to 24.9 kg/m2
  • Waist Circumference:
  • Men: < 40 inches
  • Women: < 35 inches
  • If waist circumference >35 inches in women and >40 inches in men initiate lifestyle changes and consider treatment strategies for metabolic syndrome as indicated.
  • The initial goal of weight loss therapy should be to reduce body weight by approximately 5-10 percent from baseline.

ACE Inhibition

  • Use in all patients with LVEF < 40%, and those with diabetes or chronic kidney disease indefinitely, unless contraindicated
  • Consider for all other patients

Angiotensin Receptor Blockade

  • Use in patients who are intolerant of ACE inhibitors with heart failure or post MI with LVEF less than or equal to 40%.
  • Consider in other patients who are ACE inhibitor intolerant.

Diabetes Mellitus

  • Lifestyle and pharmacotherapy to achieve HbA1C <7% may be considered.
  • Less stringent goal for may be considered (severe hypoglycemia, limited life expectancy, extensive comorbidities)


Anti-platelet therapy

A meta-analysis of randomized controlled trials by the international Cochrane Collaboration found "that the use of clopidogrel plus aspirin is associated with a reduction in the risk of cardiovascular events compared with aspirin alone in patients with acute non-ST coronary syndrome. In patients at high risk of cardiovascular disease but not presenting acutely, there is only weak evidence of benefit and hazards of treatment almost match any benefit obtained.".[1]

References

  1. Keller T, Squizzato A, Middeldorp S (2007). "Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease". Cochrane database of systematic reviews (Online) (3): CD005158. doi:10.1002/14651858.CD005158.pub2. PMID 17636787.